CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.24B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.81: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.24BUSDvs all stocks (USD)
Revenue (TTM)
275.59MUSDvs all stocks (USD)
Profit Margin
-13.51%Beta
0.2410xvs all stocks
52-Week Change
-31.67%vs all stocks
Market Capitalization
1.24BUSDvs all stocks (USD)
Enterprise Value
1.45BUSDvs all stocks (USD)
Forward P/E
11.68xPrice to Sales (TTM)
4.50xPrice to Book (MRQ)
81.45xEnterprise to Revenue
5.28xEnterprise to EBITDA
82.12xGross Margin
71.27%Profit Margin
-13.51%Operating Margin
-15.58%Return on Assets (TTM)
-0.45%Return on Equity (TTM)
-116.07%Revenue (TTM)
275.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.40USDUpdated Sep 27, 2026Quarterly Revenue Growth
10.90%Gross Profit (TTM)
201.96MUSDvs all stocks (USD)
EBITDA (TTM)
50.24MUSDvs all stocks (USD)
Net Income (TTM)
-37.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.85%Operating Cash Flow (TTM)
6.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.49MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-355.00KUSDFY2025 · Dec 31, 2025Revenue
272.30MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
67.93MUSDFY2025 · Dec 31, 2025Gross Profit
204.37MUSDFY2025 · Dec 31, 2025Operating Income
30.52MUSDvs all stocks (USD)
Pre-tax Income
-1.37MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.77MUSDFY2025 · Dec 31, 2025Net Income
-5.14MUSDFY2025 · Dec 31, 2025EBIT
22.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
50.24MUSDFY2025 · Dec 31, 2025Research & Development
20.94MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
152.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
24.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
36.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
36.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-5.14MUSDFY2025 · Dec 31, 2025Operating Cash Flow
29.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
28.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
72.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
93.00KUSDFY2025 · Dec 31, 2025Interest Paid
18.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.05MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
5.01MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-4.61MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-887.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-215.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.36MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
244.38MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-230.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-26.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.19MUSDFY2025 · Dec 31, 2025Shares Outstanding
37.48MSharesUpdated Sep 27, 2026Float Shares
28.93MSharesUpdated Sep 27, 2026Shares Short
7.49MSharesUpdated Sep 27, 2026Short Ratio
15.23daysvs all stocks
Short % of Shares Outstanding
22.23%vs all stocks
% Held by Insiders
15.38%vs all stocks
% Held by Institutions
58.56%vs all stocks
Total Cash (MRQ)
85.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.28USDUpdated Sep 27, 2026Total Debt (MRQ)
300.74MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
20.26xCurrent Ratio (MRQ)
2.24xBook Value per Share (MRQ)
0.4060USDUpdated Sep 27, 2026Total Assets
399.48MUSDvs all stocks (USD)
Total Current Assets
211.75MUSDFY2025 · Dec 31, 2025Total Liabilities
347.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
187.73MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
251.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
96.30MUSDFY2025 · Dec 31, 2025Cash
72.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
72.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
110.89MUSDFY2025 · Dec 31, 2025Inventory
13.52MUSDFY2025 · Dec 31, 2025Accounts Payable
35.35MUSDFY2025 · Dec 31, 2025Short-term Debt
887.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
788.00KUSDFY2025 · Dec 31, 2025Long-term Debt
251.09MUSDFY2025 · Dec 31, 2025Common Stock (Book)
37.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-156.52MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
52.09MUSDvs all stocks (USD)
52-Week Low
28.54USDUpdated Sep 27, 202652-Week High
54.85USDUpdated Sep 27, 202652-Week Change
-31.67%vs all stocks
Beta
0.2410xvs all stocks
50-Day MA
38.65USDUpdated Sep 27, 2026200-Day MA
40.86USDUpdated Sep 27, 2026Avg 10-Day Volume
630.35KSharesUpdated Sep 27, 2026Avg 30-Day Volume
535.82KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9900USDUpdated Sep 27, 2026Other Income / Expense
-7.70MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.14
Financial Health
Altman Z-Score 2.81: safe zoneNotable
Altman Z-Score: 2.81
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.24B, above the global median of $1.18BNotable
Market cap (USD): 1,239,723,199Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort EP MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Lukang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Carsgen Therapeutics Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow